XML 65 R46.htm IDEA: XBRL DOCUMENT
v3.26.1

Revenues (Details) € in Thousands, $ in Thousands, $ in Thousands |  |  |  |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 31, 2025 USD ($) | Jun. 28, 2021 | Mar. 16, 2021 USD ($) | Jul. 31, 2019 USD ($) | Mar. 31, 2015 USD ($) | Mar. 31, 2015 CAD ($) | Dec. 31, 2025 USD ($) | Dec. 31, 2025 EUR (€) | Sep. 24, 2024 USD ($) | Apr. 06, 2018 USD ($)
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Additional payment |  |  |  |  |  | $ 2,000 |  |  |  |
Net sales percentage |  |  |  |  | 16.50% | 16.50% |  |  |  |
Transfer price rate | 10.00% |  |  |  |  |  |  |  |  |
Terms of agreement |  |  |  | $ 750 |  |  |  |  |  |
Additional achieved milestone |  |  | $ 40,450 | 3,250 |  |  |  |  |  |
Revenues recognized |  |  |  |  |  |  | $ 2,000 |  |  |
Non-refundable payment |  |  | $ 2,250 |  |  |  |  | € 250 |  |
Milestone payment percentage |  |  |  |  |  |  | 30.00% | 30.00% |  |
Finite-lived patents, gross |  |  |  |  |  |  |  |  | $ 250 |
Maximum [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of royalties on net sales |  | 40.00% |  |  |  |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of royalties on net sales |  | 15.00% |  |  |  |  |  |  |  |
Cipher Pharmaceuticals [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  | $ 1,292 | $ 1,650 |  |  |  |
Chong Kun Dang Pharmaceuticals Corp. [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Terms of agreement |  |  |  |  |  |  | $ 1,500 |  |  |
Additional achieved milestone |  |  |  |  |  |  | 500 |  |  |
Gebro Holding GmbH [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Terms of agreement |  |  |  |  |  |  | 1,850 | € 1,500 |  |
Additional achieved milestone |  |  |  |  |  |  | $ 720 | € 600 |  |
Description of additional payments |  |  |  |  |  |  | Under the Distribution and Supply Agreement, the Company is entitled to € 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) € 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and € 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between € 750 thousand and € 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between € 300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. | Under the Distribution and Supply Agreement, the Company is entitled to € 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) € 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and € 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between € 750 thousand and € 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between € 300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. |  |
Vetbiolix [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Description of additional payments |  |  |  |  |  |  | On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (“CMS Medical”) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). | On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (“CMS Medical”) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). |  |
Revenues recognized |  |  |  |  |  |  |  |  | $ 271 |
CMS Medical Venture Investment Limited [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments payable |  |  |  |  |  |  |  |  |  | $ 2,000
Regulatory Milestones [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Additional achieved milestone |  |  |  |  |  |  | $ 14,000 |  |  |
Sales Milestones [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Additional achieved milestone |  |  |  |  |  |  | 58,500 |  |  |
Kyongbo Pharm Co Ltd [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Revenues recognized |  |  |  | $ 750 |  |  |  |  |  |
Ewopharma [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Terms of agreement |  |  |  |  |  |  | $ 2,250 |  |  |
Percentage of royalties on net sales |  |  | 17.50% |  |  |  |  |  |  |
South Korea [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Net sales percentage | 23.00% |  |  |  |  |  |  |  |  |
Liver Cancer Indication [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments payable | $ 3,000 |  |  |  |  |  |  |  |  |
NASH [Member] |  |  |  |  |  |  |  |  |  |
Revenues [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments payable | $ 6,000 |  |  |  |  |  |  |  |  |

X
- Definition Amount of additional revenue received for achieved milestone. + References No definition available. + Details
Name: | canf_AdditionalRevenueReceivedForAchievedMilestone
Namespace Prefix: | canf_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment percentage. + References No definition available. + Details
Name: | canf_MilestonePaymentPercentage
Namespace Prefix: | canf_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of non-refundable payment. + References No definition available. + Details
Name: | canf_NonRefundablePayment
Namespace Prefix: | canf_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represent the percentage of royalties on net sales. + References No definition available. + Details
Name: | canf_PercentageOfRoyaltiesOnNetSales
Namespace Prefix: | canf_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Transfer price rate. + References No definition available. + Details
Name: | canf_TransferPriceRate
Namespace Prefix: | canf_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of upfront and milestone payments payable. + References No definition available. + Details
Name: | canf_UpfrontAndMilestonePaymentsPayable
Namespace Prefix: | canf_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of upfront payment. + References No definition available. + Details
Name: | canf_UpfrontPayment
Namespace Prefix: | canf_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_FiniteLivedPatentsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 + Details
Name: | us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_GebroHoldingGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_VetbiolixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_CMSMedicalVentureInvestmentLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_KyongboPharmCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=canf_EwopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_KR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=canf_LiverCancerIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=canf_NASHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |